Krebs Biochemicals And Industries Limited (KREBSBIO)

Loading page…

Krebs Biochemicals And Industries Limited (KREBSBIO) · mywealthgrid

About

Krebs Biochemicals And Industries Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹147 Cr

P/E

—

P/B

—

Dividend yield

ROE

—

ROCE

-17%

Debt / equity

—

OPM

-23%

EPS (TTM)

₹-6.5

Book value

₹-75.5

52-week high

—

52-week low

—

2,439 historical price candles were omitted because the exchange source has not been verified.

₹68.1+20.6%1Y

Quick read

rule-based

Pros

+High promoter holding of 72.7% with no pledge

Cons

−Low return on equity of -327.4% (3-yr avg)
−Revenue shrank over the last 5 years (-15.1% a year)
−Weak interest coverage of -1.4×

Research score

Structured signal from quality, growth, valuation and momentum.

50/100

Business quality: 0
Growth: 50
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	3	34	48	33	54	53	52	50	43	24
COGS	-0	-1	13	23	16	26	41	26	7	6	0
Gross profit	—	—	21	25	18	28	12	26	44	38	23
	14	12	29	34	36	45	53	42	53	53	29
	-12	-9	-8	-10	-19	-18	-41	-16	-9	-15	-5
OPM %	-960.9%	-319.6%	-22.2%	-20.5%	-55.8%	-32.7%	-77%	-30.3%	-17.3%	-34.7%	-23%
Depreciation	4	4	4	4	5	5	6	7	7	7	6
Interest	1	3	5	6	6	6	5	3	5	6	7
	1	-0	-1	0	0	1	8	1	0	1	2
Profit before tax	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27	-17
Tax	—	—	0	0	0	0	0	0	0	0	0
Tax %	—	—	0%	0%	0%	0%	0%	0%	0%	0.1%	0%
PAT	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27	-17
PAT margin %	—	-583.6%	-52.8%	-41.9%	-86.4%	-52.8%	-84.1%	-47.4%	-39.1%	-62.2%	-71.3%
EPS (₹)	-13	-8.4	-14	-12.8	-16.8	-14.5	-20.8	-11.3	-9.2	-12.5	-7.9
EPS adjusted (₹)	-17.2	-11.7	-13	—	—	-14.5	-20.7	-11.5	-9.2	-12.5	-7.9
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	14	14	20	22	22	22	22	22
Reserves	-3	-12	-32	-62	-97	-121	-141	-168	-184
Minority interest	23	0	—	—	—	—	—	—	0
	18	43	52	111	143	183	193	212	225
	73	78	92	91	122	91	104	103	101
Total equity & liabilities	120	122	126	159	190	175	178	169	163
	102	102	102	118	139	147	150	146	142
CWIP	11	4	2	10	7	2	0	1	2
Investments	—	—	—	0	0	0	0	0	0
	7	16	21	31	45	25	28	22	20
Total assets	120	122	126	159	190	175	178	169	163

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	51.6%	52.5%	51.7%	23.2%	50.8%	86.9%	87.2%	98.4%
EBITDA margin %	-20.5%	-55.8%	-32.7%	-77%	-30.3%	-17.3%	-34.7%	-23%
EBIT margin %	-29.8%	-69.8%	-42.3%	-88.9%	-42.9%	-30.7%	-50.2%	-50%
PAT margin %	-41.9%	-86.4%	-52.8%	-84.1%	-47.4%	-39.1%	-62.2%	-71.3%
Working capital
Receivable days	—	—	2	6	4	14	0	0
Inventory days	—	—	234	230	170	543	396	5,335
Payable days	—	—	292	340	217	1,051	1,192	12,878
NWC days	—	—	-57	-105	-44	-494	-795	-7,543
Leverage
Current ratio	—	—	0.44	0.45	0.33	0.28	0.1	0.09
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	-2.59	-1.9	-1.84	-1.62	-1.45	-1.38
Interest coverage	-2.2	-3.9	-3.5	-7.3	-7.3	-3.2	-3.6	-1.4
Asset turnover	—	—	0.34	0.28	0.3	0.28	0.26	0.15
Return ratios
Return on assets %	—	—	-17.8%	-23.5%	-14.1%	-11.1%	-15.9%	-10.4%
Return on capital employed %	—	—	-19.9%	-35.1%	-18.3%	-12.4%	-23.1%	-17%
Return on equity %	—	—	66.4%	59.3%	24.8%	16.5%	18.4%	10.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%
	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%	26.76%
No. of shareholders	—	—	—	—	—	—	—	—	8,912	8,710	8,553	8,521

Promoter holding up 0 percentage points since Sep 2023.

6 deals · 13 Aug 2021 – 26 Nov 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
26 Nov 2024	GUTTIKONDA RAJASEKHAR	Bulk	NSE	Buy	1,43,843	₹115.85	₹1.67 Cr
19 Jul 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	3,71,224	₹115.16	₹4.28 Cr
19 Jul 2024	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	3,71,224	₹114.96	₹4.27 Cr
19 Jul 2024	N.G.C.S. (P) LTD.	Bulk	NSE	Sell	1,17,638	₹115.52	₹1.36 Cr
19 Jul 2024	N.G.C.S. (P) LTD.	Bulk	NSE	Buy	1,17,638	₹115.39	₹1.36 Cr
13 Aug 2021	BRESCON VENTURES PRIVATE LIMITED	Bulk	NSE	Sell	2,25,000	₹149.07	₹3.35 Cr

1–6 of 6

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. RAVI RAVINDRANATH TAGORENon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. AVINASH RAVINon-Executive - Non Independent Director
Mr. PABITRAKUMAR KALIPADA BHATTACHARYYANon-Executive - Non Independent Director
Mr. MANISH KUMAR JAINExecutive Director-CEO-MD
Mr. POPATLAL MUKANCHAND KATHARIYANon-Executive - Independent Director
Ms. DIPTI CHINUBHAI SHAHNon-Executive - Independent Director
Mr. SATYA PRAKASH CHIGURUPATINon-Executive - Independent Director
Mr. SUMANTH KARLAPUDINon-Executive - Independent Director
Mr. Ritesh JainChief Financial Officer
Mr. Rakesh KalbateCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Krebs Biochemicals And Industries Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results6 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

10 announcementsExport CSV

29 Sept 2026, 7:08 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	51.6%	52.5%	51.7%	23.2%	50.8%	86.9%	87.2%	98.4%
EBITDA margin %	-20.5%	-55.8%	-32.7%	-77%	-30.3%	-17.3%	-34.7%	-23%
EBIT margin %	-29.8%	-69.8%	-42.3%	-88.9%	-42.9%	-30.7%	-50.2%	-50%
PAT margin %	-41.9%	-86.4%	-52.8%	-84.1%	-47.4%	-39.1%	-62.2%	-71.3%
Working capital
Receivable days	—	—	2	6	4	14	0	0
Inventory days	—	—	234	230	170	543	396	5,335
Payable days	—	—	292	340	217	1,051	1,192	12,878
NWC days	—	—	-57	-105	-44	-494	-795	-7,543
Leverage
Current ratio	—	—	0.44	0.45	0.33	0.28	0.1	0.09
Debt to EBITDA	—	—	—	—	—	—	—	—
Debt to equity	—	—	-2.59	-1.9	-1.84	-1.62	-1.45	-1.38
Interest coverage	-2.2	-3.9	-3.5	-7.3	-7.3	-3.2	-3.6	-1.4
Asset turnover	—	—	0.34	0.28	0.3	0.28	0.26	0.15
Return ratios
Return on assets %	—	—	-17.8%	-23.5%	-14.1%	-11.1%	-15.9%	-10.4%
Return on capital employed %	—	—	-19.9%	-35.1%	-18.3%	-12.4%	-23.1%	-17%
Return on equity %	—	—	66.4%	59.3%	24.8%	16.5%	18.4%	10.4%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
29 Sept 2026, 7:08 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
29 Sept 2026, 12:36 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
21 Sept 2026, 11:57 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
7 Sept 2026, 10:44 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
4 Sept 2026, 2:59 pm	AGM/EGM AGM	Notice Of 34Th Annual General Meeting Of The Company	PDF
4 Sept 2026, 11:28 am	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
3 Sept 2026, 12:44 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
7 Aug 2026, 9:22 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-12	-17	-26	2	-8	-2
	-26	-23	-11	-8	-5	-4
	38	40	37	6	13	6
Net cash flow	1	-1	-0	0	0	-0
Free cash flow	-37	-44	-37	-6	-13	-6
CFO / Operating profit %	—	—	—	—	—	—

Krebs Biochemicals And Industries Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1